相关实验视频
Updated: Jan 12, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
873
抗IGF-1R反感性寡核酸CT102:对于Graves眼病的有前途的治疗剂
Yuting Zhou1, Weijie Wang1, Gengshen Song1
1Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Beijing, China.
The Journal of pharmacology and experimental therapeutics
|November 1, 2025
概括
CT102,一种针对胰岛素类生长因子-1受体 (IGF-1R) 的反感性寡核酸,显示了对格雷夫斯眼病 (GO) 的治疗潜力. 这项临床前研究证明了CT1022.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 格雷夫斯眼病 (GO) 是一种自身免疫轨道疾病,治疗选择有限.
- 在轨道纤维细胞中失调的胰岛素样生长因子-1受体 (IGF-1R) 信号传递是GO的关键致病机制.
- 针对IGF-1R的向疗法为GO提供了一个有希望的治疗策略.
研究的目的:
- 评估CT102的临床前治疗潜力,一种针对IGF-1R的反感性寡核酸,用于Graves眼病.
- 在GO大鼠模型中评估眼部CT102的安全性和有效性.
- 将CT102的治疗效果与现有治疗方法进行比较.
主要方法:
- 建立了使用牛甲状腺蛋白注射的与GO相关的老鼠模型.
- 通过高血清甲状腺过氧化酶抗体和抑制血清甲状腺刺激激素水平来验证GO模型.
- 用眼睛注射CT102并评估IGF-1R水平,病理变化和GO相关的生物标志物.
主要成果:
- 眼部CT102的使用耐受性很好.
- 高剂量的CT102治疗降低了IGF-1R水平和眼组织的病理异常.
- 与teprotumumab和miR-143.3相比,CT102治疗恢复了GO相关的生物标志物,并显示出优异的调制.
结论:
- CT102在Graves眼科病的临床前模型中显示出显著的治疗益处.
- 反IGF-1R反感性寡核酸代表了GO的潜在新疗法策略.
- 这项研究为CT102在GO患者的临床试验提供了理由.
相关概念视频
01:27Open Angle Glaucoma: Treatment
951
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
951
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476